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ABSTRACT 
 
Crystallizing RNA has been an imperative facet and a challenging task in the world of 
RNA research. Assistive methods such as Chaperone Assisted RNA Crystallography (CARC), 
employing monoclonal antibody fragments (Fabs) as crystallization chaperones have enabled us 
to obtain RNA crystal structures by increasing the crystal contacts and providing initial phasing 
information. Using this technology the crystal structure of ∆C209 P4-P6 RNA (an independent 
folding domain of the self-splicing Tetrahymena group I intron) complexed to Fab2 (high 
affinity binding Fab) has been resolved to 1.95 Å (1). Although the complexed class I ligase 
ribozyme has also been crystallized using CARC (2), in practice, it has been found that the 
crystallization of, large RNA-Fab complex remains a confrontation. The possible reason for this 
difficulty is that Fabs have not been optimized for crystallization when complexed with RNA. 
Here we have used the Surface Entropy Reduction technique (SER) for the optimization process. 
Candidate residues for mutations were identified based on combining results from visual 
inspection of ∆C209 P4-P6/Fab2 crystal structure complex using pyMOL software and a web- 
based SER software. The protruding lysine and glutamate residues were mutated to a set of 
alanine (Super Mutant Alanine SMA) and serine (Super Mutant Serine SMS) mutant clones. 
Filter binding assay studies confirmed that the mutant clones bind to ∆C209 P4-P6 with similar 
binding affinities as that of the parent Fab2. Large scale expression of the mutants, parent clone 
and ∆C209 P4-P6 RNA were optimised. Crystal trays for ∆C209 P4-P6 complexed with Fab2, 
Fab2SMA and Fab2SMS were set-up side-by-side using Hampton crystal screen kits and ~600 
conditions including temperature as a variable condition were screened. Crystal screening shows 
significantly higher crystal-forming ratios for the mutant complexes. As the chosen SER residues 
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are far away from the CDR regions of the Fab, the same set of mutations can be potentially 
applied to other Fabs binding to a variety of ribozymes and riboswitches to improve the 
crystallizability of the Fab-RNA complex. 
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CHAPTER 1  INTRODUCTION 
 
With every new discovery of a functional RNA, there is a sprint to obtain its crystal 
structure and elucidate the structure-function relationship. The dynamic RNA research is mired 
by the difficulty in obtaining RNA crystals due to its structural properties. The negatively 
charged phosphate backbone of RNA disfavors good crystal lattice formation. Compared to 
proteins, RNAs have fewer functional groups available to make crystal contacts. In addition, the 
generally weaker and flexible tertiary structure of RNAs may lead to inter-domain movements 
within RNA, making crystal packing all the more difficult (3). Assistive methods for 
crystallization are in place to alleviate these complications (4,5). Chaperone Assisted RNA 
Crystallography is one such assistive method where a monoclonal antibody fragment binds to 
RNA of interest and aids in crystallization. Antigen-binding fragments Fabs selected from a 
synthetic phage display library can bind to large functional RNAs. These Fabs with large surface 
area participate extensively in crystal contacts formation and provide good initial phasing 
information (1,2). 
YSGX synthetic superlibrary is a reduced genetic codon library, which contains randomized 
CDRs especially enriched in tyrosines and serines (6). This was used to obtain the first RNA-Fab 
complex crystal structure (1.95 Å) of ∆C209 P4-P6 binding to Fab2 (1). ∆C209 P4-P6 RNA is a 
single site mutant form of the P4-P6 of Tetrahymena group I intron which catalyses its own 
excision from precursor RNA. The single site mutation increases the tertiary stability by 
reducing the conformational flexibility of the P4 helix. This 159 nt mutant structure was resolved 
to 2.25 Å vs the wild type of 2.8 Å (7,8). Using ∆C209 P4-P6 RNA as a proof-of-concept model 
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system, Ye and coworkers have selected specific anti-RNA Fabs and demonstrated the co-
crystallization of ∆C209 P4-P6 RNA in complex of Fab2. This crystal structure further improved 
the resolution of the ∆C209 P4-P6 RNA to 1.95 Å. Fab chaperone showed great phasing 
capacity. The electron density map generated by molecular replacement using Fab solution alone 
can be used to build ∆C209 P4-P6 models. The crystal structure of ∆C209 P4-P6/Fab2 revealed 
extensive crystal contacts involving Fab-Fab and Fab-RNA intermolecular interactions. Fab 
contributed to 61% of the total surface area buried by crystal lattice interactions. These features 
validate the Fabs as good crystallization chaperones. 
Class I ligase ribozyme is another functional RNA which has been crystallized in 
complex of the Fab chaperone. Its cognate Fab BL3-6, was selected against the class I ligase 
using YSGRX synthetic Fab library with reduced codon enriched in tyrosines, serines, glycines 
and arginines (2). The structure of the class I ligase/BL3-6 complex was resolved to 3.1 Å. The 
crystal structure reveals that binding of Fab to the class I ligase doesn’t change its catalytic 
function. Molecular replacement using Fab co-ordinates provided sufficient initial phasing 
information to resolve the RNA structure. Fab BL3-6 also involved extensively in the crystal 
contact with the RNA. Together with the Fab-RNA contacts of the original complex, Fab BL3-6 
mediated crystal contacts account for 78.7% of buried surface area in the structure.  
In both Fab mediated ∆C209 P4-P6 and class I ligase ribozyme crystal structures, the 
cognate Fabs showed great phasing value and extensive crystal contact participation, 
corroborating Fabs as general crystallization chaperones for RNA targets. 
Despite these favorable features of Fabs as vital crystallization chaperones, crystallizing 
large RNAs is still an impediment. For instance, although ∆C209 P4-P6/Fab2 complex has been 
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crystallized at 4 
o
C, there were no crystal hits at 20 
o
C using Hampton Crystallization Screening 
kits. A possible reason is that although Fab in general is a great crystallization module, its 
crystallization capability was not optimized when in complex with RNA molecules. The 
nucleation event and crystal growth kinetics of Fab-RNA complexes may differ substantially 
from that of Fab alone or RNA alone. As an empirical experience, it is observed that Fab-RNA 
complexes in general are more soluble than RNA alone and less soluble than Fab alone. As a 
consequence, Fab-RNA complexes precipitate out more frequently than Fab alone and less 
frequently than RNA alone. It is reasoned that by providing large surface area to bind to large 
RNA antigen molecule, much of the Fab surface is inaccessible to make crystal contacts either 
directly or indirectly masked by RNA molecules through steric hindrance. Therefore, optimizing 
the crystallizability of the Fab module in complex of RNA may provide a solution to the low 
crystal hit rate during crystal screening of the Fab-RNA complexes. 
Developed by the Derewenda group, surface entropy reduction generates ‘low-entropy’ 
surface patches through site-directed mutagenesis to develop crystallizable variants (9-12). To 
better explain this technique, it is important to understand the thermodynamics of crystallization. 
Crystallization is a thermodynamically costly process. ∆G = ∆H-T(∆Sprotein+∆Ssolvent) represents 
the free energy change that drives crystallization. Enthalpy ∆H is considered to be a very small 
value, when compared to the entropy changes of solvent and protein. Protein molecules 
incorporated in lattices confers a negative entropy term disfavoring crystallization. The release of 
structured water molecules around the hydrophilic and hydrophobic patches on protein surface 
can contribute to positive entropy and favor protein crystallization. Amino acids with large 
flexible and charged side-chains (such as lysines and glutamates) are detrimental to the 
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crystallization process for two reasons. Large residues have high conformational entropies which 
will be lost if they are directly involved in the crystal contact. In addition, large residues are less 
likely to organize solvent molecules whose release is the major driving force of the 
crystallization process (9,11,13-16). Thus, surface entropy reduction enhances the 
crystallizability of proteins by rational mutagenesis of surface residues to decrease the surface 
entropy. The choice of lysines and glutamates pertains to the fact that they are residues found to 
be over-represented as exposed on protein surface. About 6% of lysine residues are found to be 
buried in proteins while 68% is exposed with its amino group. The rest of the 26% is found to be 
partly exposed. Only 12% of glutamic acids are found to be buried. Both the amino acids account 
for a considerable proportion of total amino acid content of many proteins (17). Their side chains 
have high conformational entropy, ~2 kcal/mol (under normal conditions) supporting the fact 
that high entropy side chain residues remain on the protein surface (18,19). In addition, the  
atomic structure of protein-protein interfaces show a stark depletion of lysine and glutamate (20). 
By replacing surface lysines and glutamates to alanines, surface entropy reduction has been used 
successfully to improve the crystallizability of many proteins and complexes (9,11).  
We will discuss the competing methods of engineering crystal contacts and SER 
approach. SER has been applied in this study to improve the crystallizabity of Fab/RNA 
complex. The expression of the mutated Fab proteins was optimized and the purified Fabs were 
complexed with ∆C209 P4-P6 and screened for crystallization. Greater crystal forming rate was 
observed with the mutant Fabs obtained through the surface entropy reduction method.  
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Single strand DNA synthesis 
 
Double stranded Fab2 plasmid was electroporated into CJ236 cells (uracil deglycosidase 
deficient E.coli) on a micropulser electroporator (Bio-Rad). Single colony from the 
transformation plate was used to inoculate 1 ml 2YT starting culture with 100 μg/ml ampicillin 
and 10 μg/ml chloramphenicol and this culture was shaken at 37 oC for 6 hrs. M13 helper phage 
(~10
10
 pfu/ml) was added to the slightly cloudy culture, and shaken for 10 min at 37 
o
C. 300 µl 
of the mixture was transferred to 30 ml 2YT with 100 µg/ml ampicillin and 0.25 µg/ml uridine 
and shaken for 18 hrs at 37 
o
C. The phage solution was purified and the uracil-containing ssDNA 
was isolated with the Qiagen M13 purification kit. The concentration of the eluted ssDNA was 
determined using a spectrophotometer reading and an agarose gel was run to verify the ssDNA 
band against a positive control. 
2.2 Kunkel Mutagenesis 
 
            The following Kunkel primers were designed for construction of Fab2SMA: 
CTTCATCTTCCCGCCATCTGATGCCCAGTTGAAATCTGGAACTGC (for LC-E123A), 
AGCAGACTACGAGAAACACGCCGTCTACGCCTGCGAAGTA (for LC-K190A), 
AGCAACACCAAGGTCGACGCCGCCGTTGCCCCCAAATCTTGTGACAAAACTCACAC
ATAGGGCCGGCCCTCTGGTTCC (for HC-K217A, HC-K218A, HC-E220A, and HC-
C230stop). Underlined are mutation sites, with GCC for alanine and TAG for amber stop codon. 
For Fab2SMS, the primers are essentially the same except that the underlined GCC was replaced 
by AGC to code for serine. The three primers were phosphorylated individually using T4 
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Polynucleotide kinase (NEB, 10U/μl) at 37 oC for ~1hr. The primers were annealed to the single 
strand template at 90 
o
C for 1 min, 50 
o
C for 3 min and placed on ice. The daughter strand 
extension was performed at 37 
o
C for 1.5 hrs using T7 DNA polymerase and T4 DNA ligase. 
PCR cleanup using Qiagen kit was performed and the Kunkel DNA was transformed into XL-
1blue cells (uracil glycosidase containing strain) by heat shock transformation. Small scale DNA 
extraction was performed on the XL-1blue cells and sent out for DNA sequencing (Genewiz 
Inc.). Stop codon was incorporated into the ∆C209 P4-P6/Fab2 gene using Kunkel mutagenesis 
to express parent ∆C209 P4-P6/Fab2 which will be used as a positive control in crystallization. 
Kunkel mutagenesis was confirmed using colony PCR. 
2.3 Fab expression of mutant clones and parent clone 
 
             Following the optimized protocol a starter culture was inoculated with Fab plasmid 
containing E coli 34B8 strain cells at 30 
o
C and 300rpm O/N in 25 ml 2YT and 100 µg/ml 
ampicillin. Spectrophotometeric reading OD at 600nm was measured and glycerol stock was 
prepared. The 5 ml of starter culture was used to inoculate 500 ml of a specialised media CRAP 
(27 mM (NH4)2SO4 , 2.4 mM sodium  citrate-2H2O,  14  mM  KCl,  5.4  g/liter  yeast extract,  
5.4  g/liter  HyCase  SF  Casein,  0.11  M  Mops– NaOH buffer (pH 7.3), 0.55% (w/v) glucose 
and 7 mM MgSO4) supplemented 100 μg/ml of ampicillin and grown at 30 
o
C and 300 rpm for 
24 hrs. OD@600nm was checked (should be >5 with good observable foaming) and the cells 
were spun down at 6000~8000 rpm for 10 min at 4 
o
C and the pellets were frozen at -80 
o
C O/N. 
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2.4 Purification of Fab2 proteins 
 
2.4.1 Protein A column-affinity chromatography 
 
The frozen cell pellets were thawed and lysed with lysozyme (0.3 mg/ml), Dnase I 
(2.5mg/30ml) in 30 ml Lysis buffer (50 mM Tris pH 8.0, 300 mM NaCl, 0.5 mM PMSF) with 
vigorous stirring for 1hr at room temperature. The cell debris was spun down at 15000 rpm for 
45 min at 4 oC. The supernatant was loaded onto the 1ml protein A column at 1ml/min. The 
column was washed with 50 column volume (CV) of 10 mM Tris pH 7.5, 500 mM NaCl at 1 
ml/min. The column was eluted with 0.1 M citric acid, pH 3, and the eluate was collected in 3 ml 
per fraction in tubes prefilled with 1.5 ml 1 M Tris pH 8.0, (mixed immediately after elution). 
After all the protein was eluted out (checked the eluted fractions on UV spectrometer), the 
column was regenerated with 3 CV of 0.1 M H3PO4, and equilibrated with 10 CV of TBS at 1 
ml/min (5 ml/min for 5 ml column). The eluted fractions were run on a SDS-PAGE gel with a 
standard protein marker and the fractions of interest were pooled together. 
2.4.2 High S resin purification-Ion exchange chromatography 
 
Fabs purified from protein A column were pooled and buffer exchanged (dialysis or 
Amicon concentration) into Low Salt NaOAc Buffer C (10 mM NaOAc, pH 5.0, 50 mM NaCl). 
High S resin suspension of 1ml was added (for 2mg < Fab <5 mg, 2 ml suspension was used, 
leading to 1 ml CV) and the column was washed with 20 CV of Low Salt NaOAc Buffer C. The 
Fab solution was loaded onto the column, and the flow through was collected. The column was 
eluted in a stepwise manner with an increasing salt gradient; 5 CV of Low Salt NaOAc Buffer C 
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(final: 50mM NaCl), 90%C/10%D (final: 100 mM NaCl), 80%C/20%D (final: 150 mM NaCl), 
70%C/30%D (final: 200 mM NaCl), 60%C/40%D (final: 250 mM NaCl), 50%C/50%D (final: 
300 mM NaCl), 40%C/60%D (final: 350 mM NaCl), or until no protein came out (checked the 
OD  at 280nm). The eluate was collected in small fractions (<=4 ml and <=5 CV) and ran on a 
SDS-PAGE. The clean Fab fractions were buffer exchanged into Fab Storage Buffer (10 mM 
Tris pH 7.5, 50 mM NaCl), aliquoted and stored in -20 
o
C. 
2.5 Large scale production of ∆C209 P4-P6 RNA 
 
The ∆C209 P4-P6 plasmid was transformed into JM109 competent cells by heat shock 
transformation. Glycerol stocks were prepared with 750 μl overnight cell culture and 150 μl 80% 
glycerol, mixed and stored at -80 
o
C. Large scale DNA extraction was done using Qiagen 
Maxiprep kit. The concentration of the extracted DNA was measured spectrophotometrically. To 
linearize the extracted plasmid a large scale Ear I digestion was carried out with100 μg plasmid, 
10x NEB buffer 4, and Ear I [final: 0.2 U/(μg plasmid)] at 37 oC, O/N. A 2% agarose gel was run 
with a 100bp ladder to check digestion. The digested DNA was PCA extracted and ethanol 
precipitated to remove salts, enzymes as well as RNAse A. 
2.5.1 Large scale in vitro transcription of ∆C209 P4-P6 RNA 
 
A typical reaction of 12 ml transcription was carried out with 10x RNA Pol Buffer (for 
1x: 40 mM Tris pH 7.9, 6 mM MgCl2, 2 mM spermidine-3HCl, 10 mM DTT), 1M MgCl2, 
25 mM NTPs, pH 7.7 (contains 25 mM of ATP, CTP, UTP, GTP), 1ug/ul Ear I linearized 
plasmid (final: 50ug plasmid/ml), autoclaved miliQ water, 4 U/μl RNase Inhibitor from Qiagen 
(final: 0.01U/ul), Tippase (final: 0.008 U/μl) and 1.13 μg/μl T7 RNAP (final: 45μg/ml) at 37 oC, 
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O/N. A 2% agarose gel was run to check the transcription. DNase I (RNase free) and CaCl2 
(final 1mM), was added to final concentration 0.5 Unit per μg of Plasmid DNA and incubated at 
37 
o
C for 30 min. Amicon filter 10 kD MWCO 50 ml falcon was used to buffer exchange the 
∆C209 P4-P6 RNA into 2 mM sodium citrate, pH 6.5, and concentrated to 1/10 original 
transcription volume (1.2 ml). A slab gel of 10% dPAGE was prepared with, 3mm x 10cm comb. 
Equal volume of 2X (50 mM Tris-HCl pH 8, 1 mM EDTA pH 8, 7 M Urea, 0.005% g/ml 
Bromophenol blue and 0.005% Xylene cyanol) RNA loading buffer was added to the 
transcription mixture, loaded onto the slab gel and ran at constant power of 15 Watts for 1.5 hrs. 
The RNA band was detected by placing the slab gel on a TLC plate with a hand held UV lamp. 
The RNA band was cut and eluted via electroelution in TE buffer, 50 volts for 12hrs at 4 
o
C. The 
elutant was concentrated to 1/10 original TXN volume, PCA extracted twice and ethanol 
precipitated immediately. The RNA was re-dissolved in TE buffer (10 mM Tris, pH 8, 1 mM 
EDTA), filtered using, Microcon centrifugal filter tubes, aliquoted and stored in -80 
o
C. 
2.6 32P labeling of ∆C209 P4-P6 RNA 
 
2l 20M transcript RNA (40 pmol), 1 l 10x Shrimp alkaline phosphatase buffer 
volume, and ll Shrimp alkaline phosphatase (SAP) were incubated at 37 oC, 30 min and 
followed by 15 min at 65 
o
C  to inactivate the SAP. 10x T4 Polynucleotide kinase buffer, 2 l  
32
P ATP and T4 PNK were added and incubated at 37 
o
C for 30 min. An analytical dPAGE 8% 
was used to purify 
32
P-labeled RNA, using 
32
P labeling gel box (plate 14 x 20 cm). The gel was 
run at constant power of 15 Watts for 1.5 hrs. The gel plate was taken out of the gel box, rinsed, 
blot dried and covered with saran wrap. Position markers were used on the gel outside of the 
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sample lanes to mark the position of the 
32
P labeled band. In dark room, one x-ray film was held 
on top of the on the gel and exposed for 30 sec. The X-ray film was developed on the film 
developer. The developed film was aligned on the gel according to the position markers and the 
gel band was marked in the back of the bottom plate. The gel band was cut and eluted in TE 
buffer on a rotator in the cold box O/N. The 
32
P labeled ∆C209 P4-P6 was PCA extracted twice 
and ethanol precipitated and saved in 
32
P coffin at -20 
o
C. 
2.7 Dot Blot Assay 
 
Dilutions of 50 μl 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, 0.156 
μM, 78 nM, 39 nM for each Fab (dilute in 1x PBS (137 mM NaCl, 0.3 mM KCl, 0.8 mM 
Na2HPO4, 0.15 mM KH2P04, pH 7.2)) in 96 well plate were made and saved at 4 
o
C. A BA85 
nitrocellulose (S&S) and Hybond N+ filter (Amersham Pharmacia) were pre-equilibrated with 
100 l  PEM (1x PBS, 0.1 mM EDTA, 10mM MgCl2), 1 mM EDTA, 10 mM MgCl2  for ∆C209 
P4-P6 binding Fabs and incubated for 15 min at room temperature. For VCIII (glycine 
riboswitch), binding Fabs, 10 mM glycine was added to the binding solution prior to the 
incubation. The P
32
labeled ∆C209 P4-P6 (~650 kcpm ) was folded in the PEM binding buffer by 
incubating at 50 
o
C for 10 min and another 10 min incubation at room temperature. RNase IN 
and 1 mg/ml Heparin were added and mixed well. The ∆C209 P4-P6/Fab2 and mutant clones 
were added to a new microtitre plate and their duplicates for each Fab dilution were made. The 
folded ∆C209 P4-P6*RNA sample at a concentration of ~0.3 nM was added to each Fab dilution 
ranging from 4 to 2000 nM and incubated for 30 min at room temperature. The dot-blot 
apparatus (Bio-Rad) was assembled as per the design protocol with nitrocellulose membrane on 
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top of Hybond membrane. After the vacuum was applied, wells were rinsed with 100 μl PEM 
binding buffer and the Fab-RNA solution (total volume of 40 μl) was transferred to the 
corresponding wells on the dot-blot apparatus. The wells were re-washed with cold binding 
buffer after the Fab-RNA solution had drained. The membranes were air dried and exposed to 
PhosphorImage screen cassette O/N. The PhosphorImage screen was scanned and the data was 
quantified using ImageQuant (Molecular Dynamics). Binding constants were calculated by 
fitting the data to the following equation: fraction bound = M  [Fab]n/( ndK  + [Fab]
n
), where Kd 
is the binding constant; M is the maximum fraction of RNA bound at the highest Fab 
concentration; and n is the Hill coefficient. 
2.8 Large scale expression of ∆C209 P4-P6/Fab2, ∆C209 P4-P6/Fab2SMA and ∆C209 P4-P6/ 
Fab2SMS 
 
The Fab expression and purification were scaled up for crystallization. The Fab clones 
were expressed as described in the Fab expression protocol (6 L CRAP media expression) and 
purified by Protein A column (5 ml column for every 3 L culture) and two rounds of High S 
resin purification. The High S resin CV was scaled up as per Fab yield after Protein A 
purification. The purity of the Fabs were checked using the nuclease test assay and then buffer 
exchanged into Fab storage buffer and stored at -80 
o
C. 
2.9 Nuclease test assay 
 
The nuclease activity test for the three Fabs were conducted by incubating the 10 μM Fab 
fractions after second round of high S with a 
32
P-labeled unrelated RNA in this case, 1 μl (~130 
kcpm) *VCLD1 for 45 mins at 37 
o
C and ran on a denaturing PAGE (pre-run for 15 mins) after 
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mixing with equal amounts of 2x RNA loading dye (50 mM Tris-HCl pH 8,1 mM EDTA pH 8,7 
M Urea, 0.005% g/ml Bromophenol blue and 0.005% Xylene cyanol). Water, TE buffer and the 
Fab storage buffer were used as negative controls. The gel was run at constant power of 15 Watts 
for 40 mins and dried in the gel drier. The dry gel was exposed to PhosphorImager screen O/N 
and the percentage of intact RNA was quantified using ImageQuant (Molecular Dynamics). 
2.10 Mobility shift Assay 
 
∆C209 P4-P6 was folded as following: 1 μl 40 μM ∆C209 P4-P6, 6.5 μl 10mM Tris 7.5, 
1 μl 250mM MgCl2, 1.5μl 1M NaCl was incubated at 50 
o
C, for 20min and set at room 
temperature for 10min. To prepare the Fab/RNA complex, 1 μl 40μM ∆C209 P4-P6, 5.7 μl 
10mM Tris 7.5, 1 μl 250mM MgCl2, 1.5 μl 1M NaCl was incubated at 50 
o
C for 20 min and set 
at room temperature for 10 min. 0.8 μl 40 μM ∆C209 P4-P6 Fab2/∆C209 P4-P6 Fab2 mutant 
was added and incubated at room temperature for 30 min. Subsequently, ∆C209 P4-P6 was run 
with ∆C209 P4-P6/Fab2, ∆C209 P4-P6/Fab2SMA and ∆C209 P4-P6/Fab2SMS complexes at 
different stoichiometric ratios of 1, 1.1, 1.2, 1.3 and 1.4 equivalents on a 8% native gel (8% 
PAGE (29:1 acrylamide:bisacrylamide), 5 mM MgCl2 filtered through 0.4 filter). The samples 
were run using 5x native gel loading dye, on a 8% native gel with Mg at room temperature, 
constant 120V for 40min. The gel was stained with ethidium bromide solution and visualized 
with UV illuminator. 
2.11 Crystal screening of ∆C209 P4-P6/Fab2 mutant complexes using sitting drop method. 
 
The folding conditions for 1 equivalent of ∆C209 P4-P6 complexed with 1.1 equivalent 
of Fab clone are as follows: ∆C209 P4-P6 (1 Eqv), 25 mM MgCl2, 50 mM NaCl, 10 mM Tris 
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HCl 7.5, were incubated at 50 
o
C for 20 min and the Fab clone (1.1 Eqv) was added along with 
0.5 mM Spermine·4HCl, RNAse inhibitor and incubated at room temperature for 30 min, spun 
down and the supernatant was collected. The drop volume used was 1μl comprising of 0.5 μl of 
sample and 0.5 μl of reservoir buffer. There were 3 crystal screens used, Hampton Crystal 
Screens I&II, Hampton Natrix Screens I&II and Hampton Index Screens with a total of over 300 
conditions. Crystal screens were carried out under both 20 
o
C and 4 
o
C conditions.  
The optimization on crystal trays was done by the hanging drop method with the buffer 
and reservoir solution in 1:1 ratio with a drop volume of 2 μl on a siliconized slide sealing a 
reservoir volume of 500 μl. The crystals from optimized trays were fished out into a 
cryoprotectant and frozen in liquid nitrogen and shipped through dry shipper to the Light 
synchrotron service at Brookhaven National Laboratory at New York. The composition of 
cryoprotectant for two optimized conditions are as follows 0.2 M DL-Malic acid pH 7.0, 22% 
w/v PEG 3, 350, 20% glycerol, 30mM MgCl2 and 0.5mM Spermine·4HCl (Figure 11A). 10 mM 
Tris pH 7.5, 2.0 M NaCl, 10% w/v PEG 6000, 20% glycerol, 30mM MgCl2 and 0.5mM 
Spermine·4HCl (Figure 11B). 
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CHAPTER 3 RESULTS AND DISCUSSION 
 
3.1 Protein Engineering and existing crystal contacts of Fabs in the Fab-RNA complexes 
 
Protein engineering techniques are widely used to assist in protein crytsallization (21). 
Understanding the physical properites of a protien is vital for engineering changes which can 
facilitate crystallization. For example the solubulity of proteins, an important criterion for 
crystallization is confered by the hydrophilic patches on surface of the protein. Systematic 
mutation on the surface of the catalytic domain of HIV-1 integrase dramtically improved its 
solubility (22,23). The other intrinsically structured elements, like the N- and C-termini which 
are very dynamic, unstructured and hinder crystallization were dealt by chopping off with 
proteolysis (24,25). The use of fusion proteins and affinity tags for obtaining crystallizable 
proteins also greatly facilitated protein crystallization (26-29). As a good crystallization module 
to begin with, Fab generally expresses well and readily crystallized alone or complexed with 
soluble protein antigens without significant efforts of surface engineering. Large amount of 
efforts on Fab crystallization were focused on the homogeneous Fab preparation and purification 
through enzymatic cleavage at the hinge region to separate Fab from the Fc portion of 
immunoglobulins as well as crystallization techniques (30,31). These Fabs or Fab antigen 
complexes can be crystallized with a good success rate without further surface engineering. 
Similarly the Fab-4D5 that our Fab framework was originated from was crystallized without 
optimization on the surface residues (32). Hence the optimization based on solubility issues or 
other purification techniques was not a major concern. 
To explore the possibility of improving crystallizability through engineered crystal 
contacts, we analyzed the frequenlty occuring crystal contacts in the Fab/RNA complex crystals 
15 
 
involving Fab4D5 derivatives. The Fab mediated crystal contacts on two of the Fab chaperone 
RNA complexes C209 P4-P6/Fab2 (PDB code: 2R8S) and class I ligase/BL3-6 (PDB code: 
3IVK) are shown in Table 1. An extended anti parallel β-sheet forming a Fab homodimer was 
found to form a main inter-molecular Fab-Fab crystal contact in the 2R8S structure. Interestingly 
this crystal contact is not found to occur in 3IVK, though both Fabs, Fab2 and Fab BL3-6 
possess identical sequence in this region. These two Fab-RNA crystal structures are the only two 
available with the Fab-4D5 framework and it has been observed that there are no crystal contacts 
or any frequent residues which are prone to make crystal contacts. Comparing the crystal 
structures of protein complexed with Fab-4D5 derivatives, full length KcSA (33) and the Fab-
4D5 structure alone, there were no conserved crystal contacts or contact residues present either. 
Lack of conserved crystal contacts of the Fab/antigen complexes is reminiscent of the common 
belief that the rational engineering of crystal contacts is a rare approach and may not be 
ubiquitously applicable (34). In analyzing the crystal contact in the 2R8S structure, besides 
crystal contacts mediated with hydrogen bonding, we noticed an important crystal contact made 
by a hydrophobic patch recognizing the extruding base and sugar R-A125 (R indicates RNA) of 
another molecule. This hydrophobic patch is composed of the non-polar part of the side-chains 
or main chains of HC-Gly42, HC-Lys43, HC-Gly44 and LC-Gln100 (HC, heavy chain; LC, light 
chain), encircling two thirds of the sugar and base moiety of R-A125 from neighboring molecule 
without the contribution of the direct hydrogen bonding. This contributes partially to the choice 
of surface engineering for crystallization enhancement. 
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3.2 Selection of the residues for surface entropy reduction for ∆C209 P4-P6/Fab2 
 
Random protein-protein interactions take place in protein crystallization making it a 
stochastic phenomenon (35). It has been reported that crystal patches favor smaller interfaces and 
polar residues. Consistent with this finding, surface entropy reduction method generates ‘low-
entropy’ surface patches through site-directed mutagenesis of the surface lysines and glutamates 
to alanines. These low-entropy surface patches act as hot-spots and promote crystallization.  
Using a model system of the globular domain of the human regulatory protein RhoGDI, the 
Derewanda group mutated and screened the protein constructs for crystallization with the SER 
approach (11,12,36,37). They found that most of the SER mutants have increased 
crystallizability while the double or triple cluster mutants (or more) involving lysines and 
glutamates in close proximity showed greatest tendency to yield new crystal forms. It has also 
been found that the crystal contacts for the double and triple mutants were in most cases directly 
mediated by the mutated epitopes (or causing steric hindrance when the wild type lysines or 
glutamates were engineered in), validating the beneficiary role of the SER mutagenesis to 
crystallization. The success in crystallization of the RhoGDI mutants has inspired the protein 
crystallographers. Many novel proteins have now been crystallized with the SER approach, 
including RGSL domain of human PDZRhoGEF (38), Y. pestis LcrV antigen (11), Tyrosine 
kinase domain of IGF-1 (39), EscJ protein (40), HIV CcmK4 capsid protein (41), etc. 
Interestingly, this approach has also enabled the crystallization of the protein complexes, such as 
the complex of c-Src and its inactivator Csk using a Csk mutant (42) and the complex of two 
pseudo-pilins EpsI and EpsJ from  the type 2 secretion  system of Vibrio vulnificus using a EpsI 
mutant (43). This application in the protein-protein complexes highlights the generality of the 
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SER approach and extends the method beyond individual component as the high-entropy patches 
occur outside complex interfaces. 
The crystallization of the protein-protein complexes using SER approach is a great 
inspiration for improving the crystallizability of Fab/RNA complexes. It suggests the possibility 
of crystallizing the macromolecular complexes by surface engineering of one single component, 
greatly increasing the generality of the Fab crystal chaperone. In addition, the SER approach 
creates local patches with reduced hydrophilicity (lysines and glutamates to alanines or serines 
mutations), consistent with our observation of the crystal contact formation (previous section). 
The probable entropy causing residues on ∆C209 P4-P6 binding Fab2 were identified by 
visual inspection of the crystal structure of ∆C209 P4-P6/Fab2 (PDB code: 2R8S) using 3D 
visualization software pyMOL. There are a total of 25 lysine residues (5.6% of total amino acids) 
and 16 Glutamate (3.5% of total amino acids) residues. Though the total lysine and glutamate 
content (10%) in Fab2 is lower than that of RhoGDI (a total of 20%), most of the lysine and 
glutamate residues are surface residues and solvent exposed. 
Based on the visual inspection of ∆C209 P4-P6/Fab2 crystal complex (2R8S) the lysine 
and glutamate residues on the surface were identified and classified into two groups. Group A 
corresponds to the most probable entropic residues HC-K76, LC-K169, LC-K190, HC-K217 and 
LC-E123. The Group B corresponds to the probable (less protruding) entropic residues LC-
K145, LC-K107, HC-K65, HC-K218, HC-K214, and HC-E220 (Figure 1).  
On studying the protruding surface residues the physical interaction of the chosen 
residues with the other residues was also taken into consideration, such as proximal residues that 
may be involved in salt or electrostatic interactions. These counter residues were also identified 
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as mutation candidates paired with their interaction partners. In the 2R8S structure, HC-E220, 
HC-K217, HC-K218, LC-E123 are clustered together and LC-E123 was found to be at an 
interacting distance (4.10 Å) with HC-K217. HC-Lys 214 and HC-Lys 218 were found to 
participate in crystal contacts using main-chain atoms while three residues (HC-Lys 217, HC-
Glu220 and LC-Glu123) form crystal contacts through side chain atoms. 
The surface-entropy reduction server (http://services.mbi.ucla.edu/SER/), recently 
developed by Eisenberg’s and Derewenda’s group, was used to strengthen the choice of the 
surface mutations (44).  
This program analyses the primary sequence of the protein entity and predicts the amino 
acids for surface entropy reduction. It takes into account the secondary structure prediction to 
which a lower score is assigned, residues predicted to be in the coil region to which higher scores 
are assigned, and the entropy profiles which are generated using side chain entropy profile tables 
(Sternberg table) whose results are normalized against lysine the highest entropic residue. At the 
last step the sequence query is subjected to PSI-BLAST to check for conserved residues and 
these residues are given a lower score (but not necessarily excluded from the mutation 
candidates). The residues with overall high scores are predicted as the top candidates for SER 
mutation. As the program does not have provision for accepting multiple peptide chains, the 
heavy chain and light chain sequences of the Fab2 were fed to the program in tandem as a single 
peptide. Table 2 summarizes the results generated by the program. Of the three clusters, Cluster 
2 sits in the cleft between constant domain and variable domain of Fab2, although it is minimally 
solvent exposed, given the location, it is very unlikely to be accessible to form intermolecular 
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contact. The residues predicted in both cluster 1 and cluster 3 overlap with the ones identified by 
visual inspection of the ∆C209 P4-P6/Fab2 crystal complex (2R8S).  
Combining both of these results, a total of five mutations were identified to begin with, 
namely HC-K217, HC-K218, HC-E220, LC-K190 and LC-E123. Construction of two super 
mutants, Supermutant Alanine (Fab2 SMA) and Supermutant Serine (Fab2SMS) were decided 
upon as to exploit the benefits of both alanine and serine residues as suggested in the study 
model of crystal structure of outer surface protein A of Borrelia burgdorferi (45). 
3.3 Construction of the ∆C209 P4-P6/Fab2 mutants 
 
Kunkel mutagenesis was used to construct the expression strains for Fab 2 Supermutant 
Alanine and Supermutant Serine (46). Single strand DNA synthesis of the phagemid encoding 
the Fab2 gene was performed. It is important to note that the phagemid encodes the Fab2 and 
phage surface protein gene III in tandem. Hence a stop codon had to be incorporated right after 
the heavy chain gene sequence to express the Fab2 alone terminating the expression of phage 
surface protein. The single strand of DNA encoding Fab2 was generated through electroporation 
into CJ236 (uracil deglycosidase deficient electrocompetent cells) and amplification with M13 
helper phage co-infection. After phage particle lysis and purification uracil rich ssDNA was 
isolated (Figure 2). The single strand DNA was used as Kunkel template to incorporate the 
respective alanine and serine mutations with specific Kunkel primers. The light chain alanine 
mutations LC-E123A and LC-K190A were introduced by seperate Kunkel primers as they lie far 
apart in the light chain. A single primer was sufficient in case of the heavy chain alanine 
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mutations including the Amber stop codon as the mutations lie in close proximity (as discussed 
above). 
 All the three Kunkel primers were annealed simultaneously with the Fab2 ssDNA. The 
alanine mutations were more efficient than the serine mutations as 3 out of 4 clones had all the 
mutations incorporated. The serine mutations did not incorporate all the mutations in one step. 
As a result, Fab2SMS were constructed with the two light chain mutations and heavy chain 
mutation introduced sequentially. Both Fab2SMA and Fab2SMS plasmids were transformed into 
the E coli 34B8 strain (a derivative of E. coli strain W3110 with the double protease deletion 
ompT/degP) (6) for expression. 
3.4  Optimization of the expression and purification of Fabs 
 
The optimization of Fab2 expression is vital for obtaining large amounts of Fabs enough 
for crystal screening. According to the previous protocol, Fabs were typically expressed in two 
steps. The first step involved inoculation of Escherichia coli 34B8 containing Fab2 gene in 25 ml 
2YT with ampicillin and shaken at 250 rpm overnight at 37 
o
C. In the second step, 10 ml 
overnight cell culture was subcultured (1/100 dilution) into 1L CRAP media in 2.8 L baffled 
flask and shaken at 250 rpm and 30 
o
C for 24 h. The Fab expression underwent some serious 
issues on following the previous protocol in the PI’s lab. Although Fab-4D5 derivatives can be 
produced in large quantity with fermentation method (47), for easy in-house replication, we 
decided to optimize Fab expression in shake flask culture. We first tried to express Fab with 
fresh colony or fresh transformation, which didn’t lead to consistent expression. Addition of 
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extra ampicillin was carried out to supplement the 24 h shaking at 30 
o
C, but the expression 
could not be revived.  
Based on the study on aeration in shake flask by McDaniel and Bailey (48) Fabs were 
expressed in aluminum-foil-capped 2.8 L baffled flask at 300 rpm with various culture volumes. 
Table 3 shows that, with starting overnight culture growing at 37 
o
C, the 1 L and 1.25 L final 
culture didn’t produce protein Fab while the 500 ml culture consistently produced Fab at ~ 1 
mg/L. This is contrary to previous observation using the same parameters where 1.25 L culture 
produced high yield (per liter) than the 1 L and 500 ml culture (1). Subtle differences in ambient 
temperature and oxygen fluctuation, oxygen rate transfer in the particular shaker may contribute 
to the difference in Fab expression in specific lab environment. Further optimization of the 
expression was carried out by lowering the starting culture temperature to 30 
o
C (Table 4), which 
increased the yield to ~3 mg/L. The higher yield with the starting culture temperature at 30 
o
C 
may be attributed to healthier cells judging from the density of the cells or reduced inorganic 
phosphates level which leads to earlier induction of the phoA promoter (49). 
Subsequently the Fabs were affinity purified on protein A column and then subjected to 
ion-exchange column purification using High S resin. One round of High S resin purification 
removes short fragments visible on the SDS-PAGE and most of the nucleases while a second 
round of High S resin purification will remove residual nuclease activity as examined by 
nuclease test, resulting clean Fab for crystal screening. The Figures 3, 4 and 5 show the SDS-
PAGE fractions of several rounds of purification of ∆C209 P4-P6/Fab2SMA, ∆C209 P4-
P6/Fab2SMS and ∆C209 P4-P6/Fab2 respectively. The nuclease test activity showed that the 
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Fabs retained minimal nuclease activity and can be used for crystallization in complex with 
∆C209 P4-P6 RNA (Figure 6). 
3.5 Characterization of Fab2SMA and Fab2SMS  
 
Filter binding assay was used to characterize the binding between mutant Fabs with 
32
P 
labeled ∆C209 P4-P6. Results (Figure 7) showed that the binding affinities of Fab2SMA and 
Fab2SMS binding to ∆C209 P4-P6 were similar to that of the parent Fab2. This is expected as 
the mutation sites were far away from the antigen binding regions. In order to set up the 
crystallization trays, it is mandatory to confirm the stoichiometric equation for complex 
formation between mutant Fabs and ∆C209 P4-P6. A native gel mobility shift assay was carried 
out (Figure 8) and the results showed that both Fab2SMA and Fab2SMS form a 1:1 complex 
with ∆C209 P4-P6, similar to Fab2. The faster mobilities of the complexes formed by either 
Fab2SMA or Fab2SMS reflect the positive charge shaved off on Fab2SMA and Fab2SMS when 
compared to Fab2. The working stoichiometric ratio (RNA : Fab = 1 : 1.1) for complete 
complexing of the RNA in the crystal screening was determined. 
3.6 Crystallization 
 
Large scale Fab expression using the protocol established above was performed. The 
typical yields of Fabs after large scale expression were around 3.8 mg/L for Fab2SMA, 2.8 mg/L 
for Fab2SMS and 2.6 mg/L for Fab2 after protein A column purification. After two rounds of 
High S resin purification, half of these yields were retained. Thus, 6-10 L cell culture provided 
sufficient Fab proteins for crystal screening. To obtain RNA with crystallizable quality, ∆C209 
P4-P6 plasmid was linearised using Ear I digestion (Figure 9). Large scale transcription (~12 ml) 
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of ∆C209 P4P6 was performed (Figure 10) followed by denaturing PAGE purification. Once the 
Fab-RNA complexes were prepared according to the determined stoichiometric ratio, the crystal 
conditions of the three complexes were screened using Hampton Crystal Screen I and II, 
Hampton Index Screen, and Hampton Natrix Screen I and II at both 20 
o
C and 4 
o
C with sitting-
drop method in the 96-3 well Intelli plates side-by-side. Considering the well solution and 
temperature, a total of ~600 conditions were screened for each Fab/RNA complex. Crystal trays 
were monitored over a period of two months. At 20 
o
C, Fab2-RNA complex did not yield any 
crystals, which is similar to the screening observed previously (1). However, three conditions for 
Fab2SMA-RNA complex and one condition for Fab2SMS-RNA complex were obtained. Figure 
11 shows the crystals and their respective crystal conditions. At 4 
o
C, crystals for all three 
complexes were obtained in Crystal Screen I 26 (Figure 11 and Table 5), from which the crystal 
structure of ∆C209 P4-P6/Fab2 complex was originally solved (1). In addition, we have also 
obtained crystals for all three complexes in a similar condition, Crystal Screen I 5 (Table 5). 
Combining the results at both 20 
o
C and 4 
o
C, crystal screens results from both 20 
o
C and 4 
o
C 
show that crystal forming rate is greatly increased with the Fab2SMA and Fab2SMS mutant 
forms. The crystal conditions obtained were then reproduced and marginally optimized by 
varying the pH, salt and precipitant concentration (depending on specific conditions) to obtain 
the range for crystal formation for different conditions (Table 6). 
 The X-ray diffraction of two preliminary crystal forms were analyzed at beam line X25 
and processed with HKL2000. The first crystal belongs to space group P1 and diffracts to 8 Å 
(condition shown in Figure 11A) while the second one belongs to space group C2 and diffracts to 
6 Å (condition shown in Figure 11B). 
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As P4-P6 was crystallized several times before (1,3,7), optimization of the crystal conditions to 
obtain bigger and better crystals were not pursued. 
The fact that Fab2SMA and Fab2SMS promote better crystal forming rates when 
complexed with ∆C209 P4-P6 proves that the surface engineering is a valuable tool for 
improving crystallizability.  
3.7 Generality of the SER mutations 
  
In order to test the generality of the SER mutations (mutations are far away from the 
CDR region of the Fabs) to Fabs binding to different antigens, all five alanine mutations were 
incorporated into two glycine riboswitch binding Fabs, VCIIIFab18 and VCIIIFab20, to 
construct VCIIIFab18SMA and VCIIIFab20SMA respectively. Expression of both Fabs gave 
reasonably good yield, ~3 mg/L. Filter binding assays show that VCIIIFab18SMA and 
VCIIIFab20SMA bind VCIII RNA with affinities similar to their corresponding parent Fabs 
(Figure 12). This result indicates that it is possible to apply the identified SER mutations to the 
Fabs with the same framework (Fab-4D5) to create a better RNA crystal chaperone. 
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Table 1: Crystal contacts residues in several Fab-4D5 derivative containing structures. 
Crystal structure   Fab-Fab Interaction Fab-antigen Interaction 
∆C209P4-P6/Fab2 
(2R8S)
a
   
H-Gly126N 
L-Glu123OE2 
H-Asn212ND2 
H-Ser211O                  
H-Thr213OG1  
H-Glu220OE1,OE2 
H-Lys217NZ 
H-Asn212O 
H-Lys214N 
H-Lys214O                             
H-Asp216N 
H-Asp216O 
                     H-Lys218N 
L-Ser202OG 
L-Gln199NE2 
L-Val110N 
L-Ser14OG 
L-Arg18N 
H-Glu89OE2 
H-Arg87NH1, 
NE 
 
 
BL3-6/BL ligase I 
(3IVK)
a 
 
 
H-Ser88OG 
L-Ser204OG 
 
H-Lys191NZ 
L-Asn211ND2 
L-Lys141NZ 
L-Thr207N 
L-Lys208NZ 
H-Gly145O 
 
FL-KcSA/Fab 
(3EFF)
a
 
 
 
H-Thr216OG1 
H-Asn215ND2 
H-Ser214O 
H-Thr127OG1 
H-Ser126OG 
 
a 
Residue number is kept the same as from PDB file and the italicized residues take part in the 
anti-parallel β sheet formation. 
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Figure 1: Crystal structure of ∆C209 P4-P6/Fab2 complex (2R8S). 
RNA is only partially shown. Five SER mutation sites are shown in yellow. Other residues 
picked by visual inspection are shown in red. The rest of the lysines and glutamates are shown in 
magenta. 
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Table 2: Query results from the web-based SERp server 
Cluster 1 Cluster 2 Cluster 3 
KADYEKHKVYACE QQKPGKAPK KKVEPK 
 
SERp score : 5.54 SERp score : 4.21 SERp score : 3.64 
 
LC-E187, K188, K190 LC-Q37, Q38, K39 HC-K217, K218, E220 
 
 
 
 
Figure 2: Single strand DNA extraction ∆C209 P4-P6/Fab2 without stop codon. 
Lane 1: 1kb Marker, Lane 3: ss DNA ∆C209P4P6Fab2, Lane 5: ss DNA VCIIIFab18, Lanes 2,4: 
empty 
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Table 3: Trials for media optimization for Fab expression - variation in media volume 
Fab2 and mutants 1L CRAP 
 
1.25L CRAP 
 
500ml CRAP 
 
OD600nm O/N 
 
7-9 
 
7-9 
 
7-9 
 
OD600nm  24 hrs 
 
4-5 
 
3-4 
 
6< 
 
Protein concentration 
 
Nil 
 
Nil 
 
1.14mg/L 
 
 
Table 4: Variation in temperature of starting culture 
∆C209P4P6Fab2SMA 
 
30 
o
C Starting culture 
 
37 
o
C starting culture 
 
O/N OD600nm 
 
7.117 
 
8.6276 
 
After 24 hr OD600nm 
 
10.485 
 
5.989 
 
Protein expression 2.12mg/L 
 
1.14mg/L 
 
 
 
Figure 3: Large scale expression and purification of ∆C209 P4-P6/Fab2SMA. 
Lane 1: Protein marker, Lane 4: Protein A column purification fraction, Lane 7:1
st
 High S resin 
purification fraction, Lane 8: 2
nd
 High S resin purification fraction 
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Figure 4: Large scale expression and purification of ∆C209 P4-P6/Fab2SMS. 
 Lane1: Protein marker, Lane 2: Protein A purification fraction, Lane 3: flow through from 1
st
 
high S resin purification, Lane 4: 1
st
 high S purification fraction, Lane 5-10: 2
nd
 high S 
purification fractions 
 
 
 
Figure 5: Large scale expression and purification of ∆C209 P4-P6/Fab2. 
Lane 1: Protein marker, Lane 2: Protein A purification fraction, Lane 3: 1
st
 high S resin 
purification fraction, Lane 4-6 2
nd
 High S purification fractions 
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Figure 6: The nuclease activity gel analysis for all the Fabs. 
Lane 1: Fab2, 87% intact *VCLD1 RNA, Lane 2: empty, Lane 3: Fab2SMA, 91% intact 
*VCLD1 RNA, Lane 4: Fab2SMS, 89% intact *VCLD1 RNA, Lane 5: Fab storage buffer, 90% 
*VCLD1 RNA, Lane 6: TE buffer, 92% *VCLD1 RNA and Lane 7: double distilled water, 92% 
*VCLD1 RNA. 
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Figure 7: Binding curves for the ∆C209 P4P6 RNA binding to Fab2, Fab2SMA and 
Fab2SMS. 
The binding affinities of ∆C209 P4-P6 with Fab2, Fab2SMA, and Fab2SMS were 122  6, 100  
3, and 77  3 nM respectively. The binding affinity of Fab2 binding to ∆C209 P4-P6 was 
previously determined to be 51 nM (1).  
 
 
Figure 8: Native gel mobility shift assay of ∆C209 P4-P6 binding to Fab2, Fab2SMA and 
Fab2SMS. 
Lane 1: ∆C209 P4-P6 RNA alone, Lane 2-4: ∆C209 P4-P6 complexes with Fab2 in molar ratio 
of 1 : 1.1, 1 : 1.2, 1 : 1.3, Lane 5-8: ∆C209 P4-P6 complexes with Fab2SMA in the molar ratio of 
1 : 1, 1 : 1.2, 1 : 1.3, 1 : 1.4, and Lane 9-12: ∆C209 P4-P6 complexes with Fab2SMS in molar 
ratio of 1 : 1, 1 : 1.2, 1 : 1.3, 1 : 1.4. 
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Figure 9: Large scale Ear I digestion of ∆C209 P4-P6 DNA. 
 Lane 1:100bp marker, Lane 2: Large scale ∆C209 P4-P6 DNA Ear I digest 
 
 
Figure 10: Large scale in vitro transcription of ∆C209 P4-P6. 
Lane 1: 100bp marker, Lane 3: ∆C209 P4-P6 large scale transcription product 
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Figure 11: Crystal pictures of ∆C209 P4-P6 complexed with Fab2 mutants from initial 
screening.  
Crystal screening was done with sitting drop method combining 0.5 μl of sample and 0.5 μl well 
solution. Sample buffer contains 10Mm Tris 7.5, 25 mM MgCl2, 50 mM NaCl, and 0.5 mM 
Spermine·4HCl. (A) Rosette crystals grew from ∆C209 P4-P6/Fab2SMA in Hampton Index 
Screen 92 (0.15M DL-Malic acid pH 7.0, 20% w/v PEG 3,350) at 20 
o
C. Initial crystals 
diffracted to 8 Å. (B) Rod-shaped crystals grew from ∆C209 P4-P6/Fab2SMS in Hampton 
Crystal Screen II 1 (2.0 M NaCl, 10% w/v PEG 6000) at 20 
o
C. Initial crystals diffracted to 6 Å. 
(C) Spherulite crystals grew from ∆C209 P4-P6/Fab2SMA in Hampton Index Screen 87 (0.2 M 
Magnesium chloride hexahydrate, 0.1 M Tris pH 8.5, 3.4M 1, 6-Hexanediol) at 20 
o
C. (D) 
Needle crystals grew from ∆C209 P4-P6/Fab2SMA in Hampton Natrix Screen 1 (0.01 M 
Magnesium chloride hexahydrate, 0.05 M MES monohydrate pH 5.6, 1.8 M Lithium sulfate 
monohydrate) at 20 
oC. (E) Single plate crystals grew from ∆C209 P4-P6/Fab2SMA crystals in 
Hampton Crystal Screen I 26 (0.2 M Ammonium acetate, 0.1 M Sodium citrate tribasic dihydrate 
pH 5.6, 30% v/v(+/-)-2-Methyl-2, 4-pentanediol) at 4 
oC. (F) Plate crystals grew from ∆C209 
P4-P6/Fab2SMS in Hampton Crystal Screen I 26 (0.2 M Ammonium acetate, 0.1M Sodium 
citrate tribasic dihydrate pH 5.6, 30% v/v(+/-)-2-Methyl-2, 4-pentanediol) at 4 
o
C. 
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Table 5: List of other crystal hits for the ∆C209 P4P6 RNA binding to Fab2 and its mutants 
RNA-Fab 
Complex 
Reservoir condition Temperature Crystal 
form 
∆C209 P4-
P6/Fab2SMA 
0.2 M Sodium citrate tribasic dihydrate,0.1M 
HEPES sodium pH 7.5,30% v/v(+/-)-2-Methyl-
2,4-pentanediol (Crystal Screen I 5) 
 
4 
o
C Plates 
∆C209 P4-
P6/Fab2SMS 
0.2 M Sodium citrate tribasic dihydrate,0.1M 
HEPES sodium pH 7.5,30% v/v(+/-)-2-Methyl-
2,4-pentanediol (Crystal Screen I 5) 
4 
o
C Plates 
∆C209 P4-
P6/Fab2 
0.2 M Sodium citrate tribasic dihydrate,0.1M 
HEPES sodium pH 7.5,30% v/v(+/-)-2-Methyl-
2,4-pentanediol (Crystal Screen I 5) 
 
4 
o
C Rosettes 
∆C209 P4-
P6/Fab2 
0.2 M Ammonium acetate,0.1M Sodium citrate 
tribasic dihydrate pH 5.6,30%v/v(+/-)-2-Methyl-
2,4-pentanediol (Crystal Screen I 26) 
4 
o
C Plates 
Drop volume: Sample : Reservoir 1:1. Sample buffer contained 10Mm  Tris 7.5, 25Mm MgCl2, 
50 Mm NaCl, 0.5Mm Spermine.4HCl 
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Table 6: Optimization of obtained crystal conditions. 
 
 
 
 
 
 
 
 
 
 
 
RNA-Fab 
complex 
Reservoir condition Optimisation range 
∆C209 P4-
P6/Fab2SMS 
2 M NaCl,10%w/v  
PEG 6000 at 20 
o
C  
1.7-2M NaCl and 10%-
13% w/v PEG 6000 
 
∆C209 P4-
P6/Fab2SMA 
0.15M DL-Malic acid pH 7.0,20%w/v PEG 
3,350 
at 20 
o
C 
0.15M-0.2M  
DL-Malic acid pH 7.0 and 
18%-22% w/v PEG 3,350 
 
∆C209P4-
P6/Fab2SMA 
0.2 M Ammonium acetate,0.1M Sodium citrate 
tribasic dihydrate pH 5.6,30%v/v(+/-)-2-Methyl-
2,4-pentanediol at 4 
o
C 
 
pH 6.0-6.2 
and 39%-45%  v/v(+/-)-2-
Methyl-2,4-pentanediol 
 
∆C209 P4-
P6/Fab2SMS 
0.2 M Ammonium acetate,0.1M Sodium citrate 
tribasic dihydrate pH 5.6,30%v/v(+/-)-2-Methyl-
2,4-pentanediol 
at 4 
o
C 
pH  5.9-6.1 
and 40%-42% v/v(+/-)-2-
Methyl-2,4-pentanediol 
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Figure 12: Surface engineered Fabs bind to VCIII glycine riboswitch. 
The binding affinities of VCIII with Fab18, Fab18SMA, Fab20 and Fab20SMA were 274  20, 
249  9, 118  5, and 182  17 nM respectively. 
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CHAPTER 4 CONCLUSION 
 
The Surface Entropy Reduction method was successfully employed to improve the 
crystallizability of ∆C209 P4-P6/Fab2 complex. Interestingly, this improved crystallizability is 
based on mutations regardless of the preexisting crystal contacts in the parent RNA Fab 
complex. Our SER mutation sites were deliberately chosen in the constant domain of the Fab so 
that there will be minimal effect on the binding between Fab and RNA. The result of VCIII RNA 
binding Fabs showed that it’s indeed possible to apply these mutations in a general manner. It 
may also be worthwhile to incorporate these mutations in the Fab framework to create a new 
phage displayed Fab library. This will eliminate the extra mutation steps involved after phage 
displayed selection if the goal is to crystallize the cognate RNA with a Fab chaperone. In 
addition, we have optimized the shake flask expression of the Fabs, which made the large 
amount of Fabs readily available for crystal screening. Combining these results, we are one step 
further in making a robust RNA crystallization chaperone. 
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